Konstanze Döhner

发表

SEURAT: Visual analytics for the integrated analysis of microarray data

Martin Sill, Axel Benner, Antony Unwin, 2010, BMC Medical Genomics.

Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma

Stephan Wolf, Peter Lichter, Thomas Boehm, 1998, Oncogene.

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

Claudio Lottaz, Stefan Fröhling, Jonathan R Pollack, 2007 .

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Manuela Zucknick, Verena I Gaidzik, Lars Bullinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization.

Stefan Fröhling, Bernhard Radlwimmer, Peter Lichter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

Lars Bullinger, Hartmut Döhner, Konstanze Döhner, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Chromosome 7: DNA Sequence and Biology

Junjun Zhang, Nazneen Rahman, Alexander K. Hudek, 2003, Science.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

Robert Tibshirani, Stefan Fröhling, Jonathan R Pollack, 2008, Blood.

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes

Sören Lehmann, Andreas Lennartsson, Verena I Gaidzik, 2014, Epigenetics.

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Lars Bullinger, Christian Buske, Wolfgang Hiddemann, 2012, Blood.

Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis

Peter Lichter, Stephan Stilgenbauer, Konstanze Döhner, 1999, Journal of Molecular Medicine.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Axel Benner, Stefan Fröhling, Hartmut Döhner, 2002, Blood.

Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases

Martin Dugas, Torsten Haferlach, Lars Bullinger, 2008 .

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Verena I Gaidzik, Lars Bullinger, Hartmut Döhner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Ulrich Mansmann, Xinan Yang, Guido Marcucci, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Verena I Gaidzik, Michael Heuser, Lars Bullinger, 2019, Nature Communications.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Stefan Fröhling, Lars Bullinger, Claudia Scholl, 2005, Blood.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia

Lars Bullinger, Hans A Kestler, Hartmut Döhner, 2011, Haematologica.

Effect of mutation order on myeloproliferative neoplasms.

Paola Guglielmelli, George S Vassiliou, Beatriz Bellosillo, 2015, The New England journal of medicine.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Michael Heuser, Daniela Weber, Hartmut Döhner, 2015, British journal of haematology.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Stefan Fröhling, Benjamin L Ebert, Todd R Golub, 2007, Cancer cell.

Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia

Mark A. Dawson, Carsten Hopf, Marcus Bantscheff, 2011 .

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Paola Fazi, Marco Vignetti, Giuseppe Avvisati, 2013, The New England journal of medicine.

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Sridhar Ramaswamy, D. Gary Gilliland, Pablo Tamayo, 2009, Cell.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.